Aberdeen Group plc Acquires 64,561 Shares of Inspire Medical Systems, Inc. $INSP

Aberdeen Group plc boosted its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 16.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 460,901 shares of the company’s stock after buying an additional 64,561 shares during the period. Aberdeen Group plc owned approximately 1.59% of Inspire Medical Systems worth $42,509,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Manning & Napier Advisors LLC purchased a new position in shares of Inspire Medical Systems in the third quarter valued at $32,000. Larson Financial Group LLC boosted its stake in Inspire Medical Systems by 21,266.7% in the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after purchasing an additional 638 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new position in Inspire Medical Systems in the 3rd quarter worth about $49,000. Daiwa Securities Group Inc. grew its holdings in Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 130 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd purchased a new position in Inspire Medical Systems during the 3rd quarter valued at about $72,000. Institutional investors own 94.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on INSP. Truist Financial cut their price objective on shares of Inspire Medical Systems from $96.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, February 12th. Wells Fargo & Company set a $70.00 target price on shares of Inspire Medical Systems and gave the stock an “equal weight” rating in a report on Thursday, February 12th. Oppenheimer cut shares of Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 22nd. Piper Sandler cut their price target on shares of Inspire Medical Systems from $165.00 to $85.00 and set an “overweight” rating for the company in a report on Thursday, February 12th. Finally, Wolfe Research lowered shares of Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a research report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $104.24.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $54.93 on Friday. Inspire Medical Systems, Inc. has a 1 year low of $48.30 and a 1 year high of $163.35. The firm has a market cap of $1.58 billion, a PE ratio of 11.03, a PEG ratio of 2.70 and a beta of 0.86. The company has a 50 day simple moving average of $61.91 and a two-hundred day simple moving average of $82.57.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.65 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.96. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. The firm had revenue of $269.08 million for the quarter, compared to analyst estimates of $264.02 million. During the same quarter in the prior year, the firm earned $1.15 EPS. The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. As a group, research analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.